Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 7, 2015, Pages 425-432

  Mohr, Erika ^a   Cox, Vivian ^a   Wilkinson, Lynne ^a   Moyo, Sizulu ^a   Hughes, Jennifer ^a   Daniels, Johnny ^a   Muller, Odelia ^a   Cox, Helen ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

ART; DR TB; HIV; Programmatic treatment outcomes

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEWBORN; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT; HIV INFECTIONS; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; STATISTICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84938492819     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trv037     Document Type: Article

References (34)

1. WHO. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014.
2. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization; 2014.
3. Abdool SSK, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2010;374:921-33.
4. National Department of Health. Multi-drug resistant tuberculosis:a policy framework on decentralised and deinstitutionalised management for South Africa. Pretoria: Department of Health; 2011.
5. O'Donnell MR, Padayatchi N, Kvasnovsky C et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013;19:416-24.
6. Farley JE, Ram M, Pan W et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 2011;6:e20436.
7. Gandhi NR, Moll A, Sturm AWet al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
8. Gandhi NR, Shah NS, Andrews JR et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-6.
9. Brust JCM, Gandhi NR, Carrara H et al. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010;14:413-9.
10. Shean K, Streicher E, Pieterson E et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013;8:e63057.
11. Isaakidis P, Varghese B, Mansoor H et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012;7:e40781.
12. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007;196(Suppl 1):S63-75.
13. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
14. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914.
15. Arentz M, Pavlinac P, Kimerling MEet al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One 2012;7:e47370.
16. Gandhi NR, Andrews JR, Brust JCM et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012;16:90-7.
17. Cox H, Hughes J, Daniels J et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014;18:441-8.
18. Daniels J, Khogali M, Mohr E et al. Time to ART initiation among patients treated for RR-TB in Khayelitsha, South Africa: impact on mortality. Int J Tuberc Lung Dis [Forthcoming; 2015].
19. Cape Town City Health. 2011 Census - Khayelitsha Health District. City of Cape Town; 2013.
20. MSF. Khayelitsha 2001-2011. Activity report 10 Years of HIV/TB care at primary health care level. Cape Town: Médecins Sans Frontières; 2011.
21. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007;196(Suppl 1):S86-107.
22. MSF. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Cape Town: Médecins Sans Frontières; 2011.
23. National Department of Health. The South African Anriretroviral Treatment Guidelines, 2013. Pretoria: Department of Health; 2013.
24. National Department of Health. National Tuberculosis Management Guidelines, 2014. Pretoria: Department of Health; 2014.
25. Cox HS, Daniels JF, Muller O et al. Impact of decentralized care and the Xpert MTB / RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha, South Africa. Open Forum Infect Dis [Forthcoming; 2015].
26. Hafkin J, Modongo C, Newcomb C et al. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana. Int J Tuberc lung Dis 2013;17:348-53.
27. Otwombe KN, Petzold M, Modisenyane T et al. Factors associated with mortality in HIV-infected people in rural and urban South Africa. Glob Helath Action 2014;7:1-10.
28. Patten GE, Cox V, Stinson K et al. Advanced HIV disease at antiretroviral therapy (ART) initiation despite implementation of expanded ART eligibility guidelines during 2007-2012 in Khayelitsha, South Africa. Clin Infect Dis 2014;59:456-7.
29. Maher D, Watt CJ, Williams BG et al. Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? Int J Tuberc lung Dis 2005;9:123-7.
30. Holmes CB, Wood R, Badri M et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42:464-9.
31. Shean KP, Willcox PA, Siwendu SN et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients , West Coast/Winelands, South Africa , 1992-2002. Int J Tuberc Lung Dis 2008;12:1182-9.
32. Kendall E, Theron D, Franke MF et al. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One 2013;8:e83480.
33. Korenromp EL, Bierrenbach AL, Williams BG, Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 2009;13:283-303.
34. Brigden G, Nyang B, du Cros P et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014;92:68-74.